FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS
La Haute Marche
Javené BP 90203
35302 FOUGERES cedex
FRANCE

MUTUAL RECOGNITION PROCEDURE
PUBLICLY AVAILABLE ASSESSMENT REPORT FOR
A VETERINARY MEDICINAL PRODUCT

SPIRAMYCINE CEVA 600 000 UI/ML
SOLUTION FOR INJECTION FOR CATTLE AND PIGS

Date: 11 July 2012
PRODUCT SUMMARY

<table>
<thead>
<tr>
<th>EU Procedure number</th>
<th>FR/V/244/001/MR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name, strength and pharmaceutical form</td>
<td>SPIRAMYCINE CEVA 600 000 UI/ML SOLUTION FOR INJECTION FOR CATTLE AND PIGS</td>
</tr>
</tbody>
</table>
| Applicant | CEVA SANTE ANIMALE  
10, av. de La Ballastière  
33500 Libourne  
FRANCE |
| Active substance(s) | Spiramycin |
| ATC Vetcode | QJ01FA02 |
| Target species | Cattle and pigs |

Indication for use

Diseases caused by spiramycin susceptible bacteria.

Cattle (adults):
Treatment of:
- Respiratory diseases,  
- Mastitis,  
- Metritis,  
- Interdigital necrobacillosis (foul in the foot).

Sows:
Treatment of mastitis.
The Summary of Product Characteristics (SPC) for this product is available on the website http://www.anmv.anses.fr/
PUBLIC ASSESSMENT REPORT

Legal basis of original application | Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
---|---
Date of completion of the original mutual recognition procedure | 27/06/2012
Date product first authorised in the Reference Member State (MRP only) | 24/10/2011
Concerned Member States for original procedure | BG, CZ, DK, EE, HU, IE, LT, LV, PL, PT, SI, SK, UK

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains 600000 IU/ml spiramycine as active substance and excipients benzyl alcohol, dimethylacetamide and water for injection.

The container/closure system is a glass vial or multi-layer plastic vial closed with rubber stopper. The particulars of the containers and controls performed are provided and conform to the regulation.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.
C. **Control of Starting Materials**

The active substance is spiramycin, an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

D. **Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies**

Certificates of suitability issued by the EDQM have been provided for spiramycin and compliance with the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products has been satisfactorily demonstrated.

There are no excipients within the scope of the TSE Guideline present or used in the manufacture of this product.

E. **Control on intermediate products**

Not applicable.

F. **Control Tests on the Finished Product**

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. **Stability**

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

An in-use shelf-life as detailed on the SPC has been supported by appropriate data.

H. **Genetically Modified Organisms**

Not applicable.

J. **Other Information**

Not applicable.
III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

Based on information provided in support of this application (one bioequivalence study in pigs and one in cattle), it is accepted that the test product is bioequivalent to the reference product SUANOVIL 20 of Merial.

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

Residue Studies

Residue depletion studies in tissues using the final formulation have been conducted in cattle and pigs.

The analytical method was fully validated.

MRLs

Spiramycin is listed in Table I of Regulation (EU) No 37/2010 of 22 December 2009. The marker substance is spiramycin 1 for pigs and sum of spiramycin + neospiramycin for cattle.
MRLs are listed below:

<table>
<thead>
<tr>
<th></th>
<th>Pigs</th>
<th>Cattle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscle</td>
<td>250 µg/kg</td>
<td>200 µg/kg</td>
</tr>
<tr>
<td>Liver</td>
<td>2000 µg/kg</td>
<td>300 µg/kg</td>
</tr>
<tr>
<td>Kidney</td>
<td>1000 µg/kg</td>
<td>300 µg/kg</td>
</tr>
<tr>
<td>Fat / skin</td>
<td></td>
<td>300 µg/kg</td>
</tr>
<tr>
<td>Milk</td>
<td></td>
<td>200 µg/kg</td>
</tr>
</tbody>
</table>

**Withdrawal Periods**

Based on the data provided above, a withdrawal period for meat of 52 days and 35 days for cattle and pigs respectively are justified.

The tested product is bioequivalent to the reference product; consequently it will be applied identical withdrawal period for milk than the reference product (10 days).

**IV. CLINICAL ASSESSMENT (EFFICACY)**

**IV.A Pre-Clinical Studies**

*Tolerance in the Target Species of Animals*

Two local tolerance studies were conducted in calves and pigs as a single intramuscular administration.

The product literature accurately reflects the type and incidence of adverse effects which might be expected.

*Resistance*

Spiramycin resistance in Europe in both target species was well documented. Adequate warnings and precautions appear on the product literature.

**IV.B Clinical Studies**

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

**V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT**

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.